Genentech Reports the Results of Inavolisib Combination Therapy in P-III Trial for the Treatment of Breast Cancer
Shots:
- The P-III (INAVO120) clinical trial evaluates the safety & efficacy of inavolisib + palbociclib + fulvestrant vs PBO + palbociclib + fulvestrant in patients (n=325) with PIK3CA-mutated, HR+ve, HER2-ve locally advanced or metastatic breast cancer. The 1EP of the study includes PFS and the 2EPs include OS, ORR & clinical benefit rate
- The results from the trial depicted that the combination of inavolisib + palbociclib + fulvestrant significantly improved PFS in breast cancer patients vs PBO + palbociclib + fulvestrant while OS statistics were still in the early stages at this time
- Inavolisib is an oral therapy with a high in vitro potency and selectivity for PI3Kα inhibition & can specifically trigger the breakdown of mutant PI3Kα protein
Ref: Genentech | Image: Genentech
Related News:- Sosei Heptares Receives $3.75M as a Part of its Multi-Target Agreement with Genentech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
